|Articles|September 14, 2021
- Pharmaceutical Executive-09-01-2021
- Volume 41
- Issue 9
Pharmaceutical Executive, September 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
When Innovation Outpaces HTA, Access Struggles to Keep Upover 4 years ago
Doubling Down On Innovation, Recoveryover 4 years ago
Developing a Product Launch Strategy for an Orphan Drugover 4 years ago
Investing for Success: Finding the Right Launch Balanceover 4 years ago
Rethinking Obesity: Wegovyover 4 years ago
Fear Factor: Palforziaover 4 years ago
Formidable Option: Orgovyxover 4 years ago
No Small Feat: Nurtec ODTover 4 years ago
‘Rare’ Reinforcement: Evrysdiover 4 years ago
Serial Problem SolverAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
2
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
3
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
4
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
5